Diamyd Medical’s associated company Cellaviva withdraws new share issue

Diamyd Medical (Nasdaq Stockholm First North, DMYD B) announces that its associated company Cellaviva has withdrawn a new share issue due to low participation in the issue.The issue was contingent upon a minimum subscription of MSEK 10.7 of a maximum subscription of MSEK 11.5. Diamyd Medical’s shareholding in Cellaviva is recognized at approximately MSEK 13.5. An impairment of the carrying amount may be required. About Diamyd MedicalDiamyd Medical is dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell and medical